Advanced Biomed Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Advanced Biomed Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($3.26M) | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | ($2.78M) | Oct 8, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $909.8K | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | $880.2K | Oct 8, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($5.83M) | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | ($2.13M) | Oct 8, 2025 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $31.7K | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | $74.1K | Oct 8, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $6.51M | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | $4.46M | Oct 8, 2025 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.03M | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | $2.80M | Oct 8, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.48M | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | $1.66M | Oct 8, 2025 |
| FY2025 | Jun 30, 2023 | $1.31M | Oct 8, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | ($19.23M) | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | ($15.97M) | Oct 8, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Oct 8, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | 0 | Oct 8, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 21.64M | Oct 8, 2025 |
| FY2025 | Dec 31, 2024 | 20.00M | Oct 8, 2025 |
| FY2025 | Oct 15, 2024 | 100.00M | Oct 8, 2025 |
| FY2025 | Jun 30, 2024 | 20.00M | Oct 8, 2025 |
| FY2025 | May 16, 2023 | 100.00M | Oct 8, 2025 |